Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China

Objective: This study is to evaluate the costs, clinical efficacy, and social benefits of a patient assistance program (PAP) implemented by the China Primary Healthcare Foundation for the use of pemetrexed as a first-line non-squamous non-small cell lung cancer (NSCLC) maintenance therapy in China.

Methods: A survival analysis was conducted on the clinical data of 1,366 patients who participated in the PAP. The progression-free survival (PFS) and median maintenance treatment cycle of pemetrexed were analyzed. A 36-month Markov model from a payer’s perspective was constructed to analyze the cost and effectiveness associated with the PAP for pemetrexed. The inputs of the model were sourced from the PAP clinical database and published literature. The study estimated the incremental quality adjusted life-years (QALYs) (pemetrexed plus best supportive care [BSC] vs BSC only), the cost saving of the PAP, the impact on the percentage of catastrophic health expenditures (CHE), and poverty headcount ratio (HCR).

Results: The median of PFS and maintenance treatment cycles were 187 days and five cycles (total nine cycles, which included four cycles of induction therapy), respectively. The pemetrexed plus BSC treatment with PAP resulted in an additional 0.12 QALYs over BSC only. The total cost was $48,034.46 and $96,191.57 for the patients who had or had not joined the PAP in 3 years, respectively. Compared to the patients without PAP, the percentage of CHE and HCR with PAP was reduced from 98.39% to 19.91% and 66.98% to 4.89%, respectively, indicating that the PAP substantially decreased the number of patients who had CHE and fallen into poverty.

Conclusion: The study concluded that the pemetrexed PAP generated noticeable clinical and economic benefits to society and to patients. The program also increased patients’ compliance with chemotherapy by allowing patients, for whom the pemetrexed treatment was unaffordable, to continue to receive it.     

台湾地区"全民健康保险"制度对癌症患者医疗保障的启示

癌症多年来占据疾病死因顺位榜首,不仅严重威胁居民的健康和生命,更让患者面临较大的医疗费用支付压力。本文介绍了我国台湾地区“全民健康保险”制度在癌症患者医疗保障方面的特点,包括通过免除个人部分负担等措施为癌症患者提供经济协助、为癌症终末期患者提供安宁疗护、实行卫生技术评估、开展“全民健康保险”信息化建设。台湾地区的经验为改善癌症患者医疗保障带来以下启示:提高现行社会医疗保险对癌症相关医疗费用支付的待遇;推动社区开展癌症的慢性病管理;利用卫生技术评估匹配癌症治疗新药及新技术的医保准入与定价;以信息化建设助力肿瘤诊疗。     

3200例宫颈液基细胞学筛查分析

为探讨宫颈癌普查工作中宫颈液细胞学诊断与组织病理学诊断的符合情况,对宫颈液基细胞学检查结果异常者做阴道镜及宫颈多点活检行组织病理学检查。细胞学诊断采用TBS(2001)分级报告系统,阳性诊断包括意义不明的不典型鳞状细胞(ASC-US)以上病变,细胞学结果与阳性病例组织学诊断结果进行对照分析。结果为10例HSIL组织病理诊断对照中有9例≥CINⅡ,占90%;25例LSIL组织病理学诊断中有13例CINⅠ,占52%;18例ASC-H组织病理诊断中有15例≥CINⅡ,占83.3%;123例ASC-US组织病理诊断中有47例CINⅠ,6例≥CINⅡ。宫颈细胞学检查是筛查宫颈癌及癌前病变的一种有效方法,对已婚妇女宫颈液细胞学普查中进行宫颈癌的筛查是非常必要的。     

Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC

Aim: To estimate the healthcare utilization and costs in elderly lung cancer patients with and without pre-existing chronic obstructive pulmonary disease (COPD).

Methods: Using Surveillance, Epidemiology and End Results (SEER)-Medicare data, this study identified patients with lung cancer between 2006–2010, at least 66 years of age, and continuously enrolled in Medicare Parts A and B in the 12 months prior to cancer diagnosis. The diagnosis of pre-existing COPD in lung cancer patients was identified using ICD-9 codes. Healthcare utilization and costs were categorized as inpatient hospitalizations, skilled nursing facility (SNF) use, physician office visits, ER visits, and outpatient encounters for every stage of lung cancer. The adjusted analysis was performed using a generalized linear model for healthcare costs and a negative binomial model for healthcare utilization.

Results: Inpatient admissions in the COPD group increased for each stage of non-small cell lung cancer (NSCLC) compared to the non-COPD group per 100 person-months (Stage I: 14.67 vs 9.49 stays, p?<?.0001; Stage II: 14.13 vs 10.78 stays, p?<?.0001; Stage III: 28.31 vs 18.91 stays, p?<?.0001; Stage IV: 49.5 vs 31.24 stays, p?<?.0001). A similar trend was observed for outpatient visits, with an increase in utilization among the COPD group (Stage I: 1136.04 vs 796 visits, p?<?.0001; Stage II: 1325.12 vs 983.26 visits, p?<?.0001; Stage III: 2025.47 vs 1656.64 visits, p?<?.0001; Stage IV: 2825.73 vs 2422.26 visits, p?<?.0001). Total direct costs per person-month in patients with pre-existing COPD were significantly higher than the non-COPD group across all services ($54,799.16 vs $41,862.91). Outpatient visits represented the largest cost category across all services in both groups, with higher costs among the COPD group ($41,203 vs $31,140.08).

Conclusion: Healthcare utilization and costs among lung cancer patients with pre-existing COPD was ～2–3-times higher than the non-COPD group.     

彩色多普勒超声与磁共振成像在原发性肝外胆管癌患者诊断中的价值差异

目的：探讨彩色多普勒超声与磁共振成像（MRI）在原发性肝外胆管癌患者诊断中的应用价值。方法回顾性分析120例原发性肝外胆管癌患者彩色多普勒超声和MRI资料,比较两种检查方法诊断的阳性率、误诊率、漏诊率及梗阻部位准确率。结果两种检查方法对肝外胆管癌诊断的阳性率、误诊率及梗阻部位准确率差异无统计学意义（P＞0.05）;但彩色多普勒超声检查漏诊率明显高于MRI（P＜0.05）。结论彩色多普勒超声可作为肝外胆管癌首选影像学筛查方法,但对于临床高度怀疑肝外胆管癌、而彩色多普勒超声未检出者应加行 MRI,以提高诊断的准确性。     

雷替曲塞联合伊立替康治疗晚期结肠癌患者的疗效及安全性

目的 探讨雷替曲塞联合伊立替康治疗晚期结肠癌患者的疗效及安全性.方法 选取2018年1月至2019年12月沈阳市肛肠医院收治的50例晚期结肠癌患者作为研究对象,按治疗方案不同分为对照组与观察组,各25例.对照组采用伊立替康、5-氟尿嘧啶和亚叶酸钙治疗,观察组给予伊立替康联合雷替曲塞治疗,比较两组治疗效果及安全性.结果 ...     

非小细胞肺癌靶向治疗药物的疗效及经济性研究综述

目的综述非小细胞肺癌靶向治疗药物的临床疗效及药物经济学评价结果。方法基于非小细胞肺癌的流行病学特征和治疗发展趋势,选取临床应用较多的靶向治疗药物,并检索国内外相关文献,对其治疗非小细胞肺癌的临床疗效和经济性进行综合分析。结果吉非替尼和厄洛替尼是目前针对非小细胞肺癌最受关注的靶向治疗药物。针对不同类型的患者,两者表现出不同的临床疗效,而较少的药物经济学研究显示了其经济性。结论吉非替尼和厄洛替尼的临床疗效和经济性在总体上优于其它治疗方案,但还需更深入的研究。     

短肽型肠内营养剂对结直肠癌围手术期患者的影响

目的探讨短肽型肠内营养剂对结直肠癌围手术期患者的影响。方法选取2017年6月至2019年8月滨州医学院附属医院收治的结直肠癌手术患者104例作为研究对象,随机分为试验组和对照组,各52例。试验组采用短肽型肠内营养剂进行营养支持,对照组患者采用传统清洁灌肠,比较患者手术前1 d及术后1 d、3 d、7 d IgC、IgA、IgM、CD3^+、CD4^+、CD8^+水平和术中肠道清洁情况。结果术后7 d,CD3^+、CD4^+逐渐升高,试验组的升高情况明显优于对照组,差异有统计学意义(P<0.05)。试验组患者术中肠道清洁情况与对照组比较,差异无统计学意义(P>0.05)。结论对结直肠癌患者围手术期采用短肽型肠内营养剂进行治疗,有利于患者术后免疫功能恢复。     

中西医结合治疗肺尘埃沉着病合并慢性阻塞性肺疾病患者的疗效

目的探讨噻托溴铵联合黄根片治疗肺尘埃沉着病合并慢性阻塞性肺疾病患者的临床疗效。方法选取2017年12月至2019年2月郴州市疾病预防控制中心收治的肺尘埃沉着病合并慢性阻塞性肺疾病患者157例为观察组,选取同期郴州市疾病预防控制中心收治的肺尘埃沉着病合并慢性阻塞性肺疾病患者143例为对照组。两组均予以吸氧、止咳祛痰平喘、肺灌洗、预防感染、康复训练等常规对症治疗。对照组患者吸入噻托溴铵粉雾剂,观察组在对照组基础上口服黄根片。比较治疗前后两组中医临床症状积分、肺功能、生命质量评分及血清白细胞介素(IL-1)、肿瘤坏死因子-α(TNF-α)水平。结果治疗前,两组中医临床症状积分、用力肺活量(FVC)、第一秒钟用力呼气容积(FEV1)、每分钟最大通气量(MVV)、生命质量评分及血清IL-1、TNF-α水平比较,差异无统计学意义(P>0.05);治疗后,两组FVC、FEV1及MVV高于治疗前(P<0.05),且观察组高于对照组(P<0.05);治疗后,两组各中医临床症状积分,症状、活动受限、疾病影响评分及生命质量总评分,血清IL-1、TNF-α水平低于治疗前(P<0.05),且观察组低于对照组(P<0.05)。结论噻托溴铵联合黄根片治疗肺尘埃沉着病合并慢性阻塞性肺疾病患者可改善其临床症状与肺功能,提高生命质量。     

Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study

Abstract

Aims: The objective of this feasibility study was to determine the extent to which data from randomized controlled trials (RCTs) may serve as a useful source for collecting health care resource use (HCRU) for the purposes of estimating costs of managing adverse events (AEs), specifically, grade 3–4 nausea and thrombocytopenia, which may be experienced during chemotherapy treatment.

Materials and Methods: The feasibility study was conducted in four steps: (1) HCRU data were extracted from patient narratives in four phase 3 RCTs in non–small cell lung cancer; (2) missing HCRU data were imputed; (3) unit costs were applied to the resulting HCRU data set and costs of managing AEs were estimated; and (4) the overall utility of using RCT data as a source for estimating costs of AEs was evaluated.

Results: 33 nausea and 68 thrombocytopenia AEs met eligibility criteria and were evaluated in this study. Medication usage was recorded as a treatment in 76% of nausea AEs, although only 14% of the instances of medication usage included the minimum data elements required for costing. Platelet transfusions were provided in 24% of thrombocytopenia AEs; however, in only one instance were the minimum data elements recorded. Of nausea and thrombocytopenia AEs, 18% and 72%, respectively, required no missing data assumptions or imputation.

Limitations: Only two AEs were considered, and they may not be representative of all AEs in terms of suitability for use in estimating HCRU and costs of managing AEs. Not all grade 3–4 AEs met the criteria for requiring a patient narrative. HCRU data in the narratives were incomplete.

Conclusions: The usefulness of RCTs for estimating the costs of AEs may be improved by using a standardized form to collect HCRU data for key AEs, including an appropriate level of detail required to estimate costs of managing the AEs.